US20150210987A1 - Recombinant microorganisms and methods of use thereof - Google Patents

Recombinant microorganisms and methods of use thereof Download PDF

Info

Publication number
US20150210987A1
US20150210987A1 US14/609,420 US201514609420A US2015210987A1 US 20150210987 A1 US20150210987 A1 US 20150210987A1 US 201514609420 A US201514609420 A US 201514609420A US 2015210987 A1 US2015210987 A1 US 2015210987A1
Authority
US
United States
Prior art keywords
bacterium
lactate
enzyme
clostridium
parental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/609,420
Other languages
English (en)
Inventor
Shilpa Nagaraju
Bakir Al-Sinawi
Sashini De Tissera
Michael Koepke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzatech NZ Inc
Original Assignee
Lanzatech New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzatech New Zealand Ltd filed Critical Lanzatech New Zealand Ltd
Priority to US14/609,420 priority Critical patent/US20150210987A1/en
Assigned to LANZATECH NEW ZEALAND LIMITED reassignment LANZATECH NEW ZEALAND LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AL-SINAWI, BAKIR, DE TISSERA, SASHINI, KOEPKE, MICHAEL, NAGARAJU, Shilpa
Publication of US20150210987A1 publication Critical patent/US20150210987A1/en
Assigned to VENTURE LENDING & LEASING VIII, INC., VENTURE LENDING & LEASING VII, INC. reassignment VENTURE LENDING & LEASING VIII, INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LANZATECH FREEDOM PINES BIOREFINERY LLC, LANZATECH HONG KONG LIMITED, LANZATECH NEW ZEALAND LIMITED, LANZATECH PRIVATE LIMITED, LANZATECH UK LIMITED, LANZATECH, INC.
Priority to US16/856,841 priority patent/US11549103B2/en
Assigned to LANZATECH NZ, INC. reassignment LANZATECH NZ, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: LANZATECH NEW ZEALAND LIMITED
Assigned to LANZATECH UK LIMITED, LANZATECH NEW ZEALAND LIMITED, LANZATECH, INC., LANZATECH HONG KONG LIMITED, LANZATECH FREEDOM PINES BIOREFINERY LLC, LANZATECH PRIVATE LIMITED reassignment LANZATECH UK LIMITED RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: VENTURE LENDING & LEASING VII, INC., VENTURE LENDING & LEASING VIII, INC.
Assigned to LANZATECH NZ, INC. reassignment LANZATECH NZ, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE U.S. PATENT NUMBER 8,979,228 PREVIOUSLY RECORDED AT REEL: 059911 FRAME: 0400. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: LANZATECH NEW ZEALAND LIMITED
Assigned to LANZATECH NZ INC. reassignment LANZATECH NZ INC. CORRECTIVE ASSIGNMENT TO CORRECT THE THE PATENT NUMBE 9,5348,20 PREVIOUSLY RECORDED AT REEL: 059911 FRAME: 0400. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: LANZATECH NEW ZEALAND LIMITED
Assigned to LANZATECH NZ, INC. reassignment LANZATECH NZ, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NAGARAJU, Shilpa, AL-SINAWI, BAKIR, DE TISSERA, SASHINI, KOEPKE, MICHAEL
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C12P7/065—Ethanol, i.e. non-beverage with microorganisms other than yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/54—Acetic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • acetogen is a microorganism that generates or is capable of generating acetate as a product of anaerobic respiration.
  • acetogens are obligately anaerobic bacteria that use the Wood-Ljungdahl pathway as their main mechanism for energy conservation and for synthesis of acetyl-CoA and acetyl-CoA-derived products, such as acetate and ethanol (Ragsdale, Biochim Biophys Acta , 1784: 1873-1898, 2008).
  • acetogens such as Clostridium autoethanogenum, Clostridium ljungdahlii, Clostridium ragsdalei (Köpke, Appl Environ Microbiol , 77: 5467-5475, 2011), and Butyribacterium methylotrophicum (Heiskanen, Enzyme Microb Technol , 41 362-367, 2007) may produce lactate as a byproduct. This production of lactate reduces the efficiency and yield of target products, such as ethanol, butanol, or 2,3-butanediol.
  • target products such as ethanol, butanol, or 2,3-butanediol.
  • lactate may be toxic to acetogens such as Clostridium autoethanogenum even at low concentrations (Köpke, Appl Environ Microbiol , 77: 5467-5475, 2011) and may serve as a substrate for other bacteria, increasingly the likelihood of bacterial contamination when lactate is produced. Furthermore, separating lactate from other products, such as ethanol, may require cumbersome processing steps.
  • the invention provides a carboxydotrophic acetogenic bacterium comprising a disrupting mutation in a lactate biosynthesis pathway enzyme.
  • the disrupting mutation reduces or eliminates the expression or activity of the lactate biosynthesis pathway enzyme.
  • the disrupting mutation affects the ability of the bacterium to produce lactate.
  • the bacterium of the invention produces a reduced amount of lactate compared to a parental bacterium. In one embodiment, the bacterium of the invention produces substantially no lactate.
  • the bacterium of the invention may produce products, such as one or more of ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate.
  • the bacterium of the invention produces an increased amount of one or more of ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate compared to a parental bacterium.
  • the lactate biosynthesis pathway enzyme is an enzyme that natively converts pyruvate to lactate.
  • the lactate biosynthesis pathway enzyme is lactate dehydrogenase (LDH).
  • the bacterium of the invention may be derived from a parental bacterium, such as Clostridium autoethanogenum, Clostridium ljungdahlii , and Clostridium ragsdalei .
  • the parental bacterium is Clostridium autoethanogenum deposited under DSMZ accession number DSM23693.
  • the invention further provides a method of producing a product comprising culturing the bacterium of the invention in the presence of a substrate comprising CO whereby the bacterium produces a product.
  • FIG. 1 is a diagram showing a LDH knockout strategy and the primers used for screening.
  • FIG. 2 is a set of gel images.
  • the first gel image shows screening for single crossover integration of knockout plasmid using primers Og24r/Og35f for 5′ crossover and Og21f/Og36r for 3′ crossover in wild type (w) and transconjugant clone 6 (6).
  • the second gel image shows screening for double crossover using outer flanking primers Og35f/Og36r and Og21f/Og24r.
  • FIG. 3 is a gel image showing colony PCR for Gene ID: 126803 Target 129S using primers LdhAF/R.
  • a PCR product of 100 bp indicated a wild-type genotype, while a product size of approximately 1.9 kb confirmed the insertion of the group II intron in the target site.
  • FIG. 4 is a gel image showing plasmid loss with primers CatPR/RepHF. The plasmid loss was checked by amplification of the resistance marker (catP) and the gram positive origin of replication (pCB102).
  • FIG. 5A is a graph showing HPLC analysis of C. autoethanogenum after 6 days of growth in serum bottles with 30 psi steel mill off-gas (44% CO, 22% CO 2 , 2% H 2 , 32% N 2 ) as substrate.
  • FIG. 5B is a graph showing HPLC analysis of C. autoethanogenum with inactivated lactate dehydrogenase after 6 days of growth in serum bottles with 30 psi steel mill off-gas (44% CO, 22% CO 2 , 2% H 2 , 32% N 2 ) as substrate.
  • the inventors have discovered that disruption of the lactate biosynthesis pathway in an acetogenic bacterium results in increased or more efficient production of products, such as ethanol, 2,3-butanediol, formate, succinate, 2-oxogluterate, valine, leucine, and isoleucine, compared to a parental microorganism, and may also result in increased or more efficient production of pyruvate, malate, fumarate, and citrate, which are precursors of succinate, 2-oxogluterate, valine, leucine, and isoleucine.
  • the production of valine, leucine, formate, and pyruvate also obviates the need to supplement culture media with these compounds, which may result in further cost savings. Furthermore, reduction or elimination of lactate production by a bacterium reduces or eliminates the toxic effects of lactate on the bacterium.
  • the invention provides a carboxydotrophic acetogenic bacterium comprising a disrupting mutation in a lactate biosynthesis pathway enzyme.
  • “Mutation” refers to a modification in a nucleic acid or protein in the bacterium of the invention compared to the wild-type or parental microorganism from which the bacterium of the invention is derived.
  • the term “genetic modification” encompasses the term “mutation.”
  • the mutation may be a deletion, insertion, or substitution of one or more nucleotides in a gene encoding an enzyme.
  • the mutation may be a deletion, insertion, or substitution of one or more amino acids in an enzyme.
  • the mutation is a “disrupting mutation” that reduces or eliminates (i.e., “disrupts”) the expression or activity of a lactate biosynthesis pathway enzyme.
  • the disrupting mutation may partially inactivate, fully inactivate, or delete a lactate biosynthesis pathway enzyme or a gene encoding the enzyme.
  • the disrupting mutation may be a knockout (KO) mutation.
  • the disrupting mutation may be any mutation that reduces, prevents, or blocks the biosynthesis of lactate.
  • the disrupting mutation may include, for example, a mutation in a gene encoding a lactate biosynthesis pathway enzyme, a mutation in a genetic regulatory element involved in the expression of a gene encoding a lactate biosynthesis pathway enzyme, the introduction of a nucleic acid which produces a protein that reduces or inhibits the activity of a lactate biosynthesis pathway enzyme, or the introduction of a nucleic acid (e.g., antisense RNA, siRNA, CRISPR) or protein which inhibits the expression of a lactate biosynthesis pathway enzyme.
  • a nucleic acid e.g., antisense RNA, siRNA, CRISPR
  • the disrupting mutation results in a bacterium of the invention that produces no lactate or substantially no lactate or a reduced amount of lactate compared to the parental bacterium from which the bacterium is derived.
  • the bacterium of the invention may produce no lactate or at least about 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% less lactate than the parental bacterium.
  • the bacterium of the invention may produce less than about 0.001, 0.01, 0.10, 0.30, 0.50, or 1.0 g/L lactate.
  • unmodified C. autoethanogenum LZ1561 may produce up to about 2 g/L lactate. Other unmodified bacterial strains may produce even more lactate.
  • the disrupting mutation may be introduced using any method known in the art. Exemplary methods include heterologous gene expression, gene or promoter insertion or deletion, altered gene expression or inactivation, enzyme engineering, directed evolution, knowledge-based design, random mutagenesis methods, gene shuffling, and codon optimization. Such methods are described, for example, in Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Pleiss, Curr Opin Biotechnol , 22: 611-617, 2011; and Park, Protein Engineering and Design, CRC Press, 2010.
  • the disrupting mutation may be introduced using nucleic acids, such as single-stranded or double-stranded DNA, RNA, cDNA, or combinations thereof, as is appropriate.
  • the nucleic acids may be referred to as constructs or vectors, and may include one or more regulatory elements, origins of replication, multicloning sites, and/or selectable markers.
  • the nucleic acid may be adapted to disrupt a gene encoding a lactate biosynthesis pathway enzyme in a parental bacterium.
  • the nucleic acid may be adapted to allow expression of one or more genes encoded by the nucleic acid.
  • Constructs or vectors may include plasmids (e.g., pMTL, pIMP, pJIR), viruses (including bacteriophages), cosmids, and artificial chromosomes.
  • constructs may remain extra-chromosomal upon transformation of a parental bacterium or may be adapted for integration into the genome of the bacterium. Accordingly, constructs may include nucleic acid sequences adapted to assist integration (e.g., a region which allows for homologous recombination and targeted integration into the host genome) or expression and replication of an extrachromosomal construct (e.g., origin of replication, promoter, and other regulatory sequences).
  • the nucleic acids may be introduced using homologous recombination.
  • Such nucleic acids may include arms homologous to a region within or flanking the gene to be disrupted (“homology arms”). These homology arms allow homologous recombination and the introduction, deletion, or substitution of one or more nucleotides within the gene to be disrupted. While it is preferred that the homology arms have 100% complementarity to the target region in the genome, 100% complementarity is not required so long that the sequence is sufficiently complementary to allow for targeted recombination with the target region in the genome.
  • the homology arms will have a level of homology which would allow for hybridization to a target region under stringent conditions (Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
  • Knowledge of the target nucleic acid sequences in a parental bacterium is generally sufficient to design appropriate homology arms.
  • the flanking homology arms described herein may be used (e.g., SEQ ID NOs: 1-2).
  • homology arms may be designed based on GenBank CP001666.1.
  • homology arms may be designed based on other publically available nucleic acid sequence information.
  • the “lactate biosynthesis pathway” is a pathway of reactions resulting in the production of lactate.
  • the lactate biosynthesis pathway comprises one or more enzymes that convert pyruvate to lactate.
  • the lactate biosynthesis pathway comprises a lactate dehydrogenase enzyme.
  • a number of different enzymes may be involved in the lactate biosynthesis pathway.
  • a bacterium comprises two or more enzymes in the lactate biosynthesis pathway, e.g., two or more enzymes capable of converting pyruvate to lactate, disrupting more than one such enzyme may have the effect of increasing the production of a product above the level that may be achieved by disrupting a single enzyme.
  • the bacterium comprises disrupting mutations in two, three, four, five, or more enzymes capable of converting pyruvate to lactate. While disrupting expression and/or activity of all such enzymes may provide some advantage in terms of product production, it is not generally necessary to disrupt expression and/or activity of all such enzymes to gain the benefits of the invention, namely increased production of one or more main or target products.
  • the lactate biosynthesis pathway enzyme natively (i.e., endogenously or naturally) converts pyruvate to lactate, such that the enzyme has lactate dehydrogenase activity.
  • the enzyme may have additional catalytic functions so long as it also converts pyruvate to lactate.
  • the enzyme may be any dehydrogenase having lactate dehydrogenase activity.
  • the introduction of a disrupting mutation to the enzyme that converts pyruvate to lactate reduces or eliminates (i.e., “disrupts”) the expression or activity of that enzyme.
  • the lactate biosynthesis pathway enzyme is lactate dehydrogenase (LDH).
  • LDH lactate dehydrogenase
  • the bacterium of the invention may comprise one or more other genetic modifications in addition to a disrupting mutation in a lactate biosynthesis pathway enzyme, including genetic modifications of one or more genes or proteins not associated with the lactate biosynthesis pathway.
  • the bacterium of the invention may express an inhibitor of a lactate biosynthesis pathway enzyme in addition to or instead of comprising a disrupting mutation in a lactate biosynthesis pathway enzyme.
  • Enzyme activity refers broadly to enzymatic activity, including, but not limited, to the activity of an enzyme, the amount of an enzyme, or the availability of an enzyme to catalyze a reaction. Accordingly, “decreasing” or “reducing” enzyme activity includes decreasing or reducing the activity of an enzyme, the amount of an enzyme, or the availability of an enzyme to catalyze a reaction.
  • An enzyme is “capable of converting” a first compound or substrate into a second compound or product, if it can catalyze a reaction in which at least a portion of the first compound is converted into the second compound.
  • variants includes nucleic acids and proteins whose sequence varies from the sequence of a reference nucleic acid and protein, such as a sequence of a reference nucleic acid and protein disclosed in the prior art or exemplified herein.
  • the invention may be practiced using variant nucleic acids or proteins that perform substantially the same function as the reference nucleic acid or protein.
  • a variant protein may perform substantially the same function or catalyze substantially the same reaction as a reference protein.
  • a variant gene may encode the same or substantially the same protein as a reference gene.
  • a variant promoter may have substantially the same ability to promote the expression of one or more genes as a reference promoter.
  • variants of a nucleic acid may include allelic variants, fragments of a gene, mutated genes, polymorphisms, and the like.
  • homologous genes from other microorganisms are also examples of functionally equivalent variants. These include homologous genes in species such as Clostridium acetobutylicum, Clostridium beijerinckii , or Clostridium ljungdahlii , the details of which are publicly available on websites such as Genbank or NCBI.
  • Functionally equivalent variants also includes nucleic acids whose sequence varies as a result of codon optimization for a particular organism.
  • a functionally equivalent variant of a nucleic acid will preferably have at least approximately 70%, approximately 80%, approximately 85%, approximately 90%, approximately 95%, approximately 98%, or greater nucleic acid sequence identity (percent homology) with the referenced nucleic acid.
  • a functionally equivalent variant of a protein will preferably have at least approximately 70%, approximately 80%, approximately 85%, approximately 90%, approximately 95%, approximately 98%, or greater amino acid identity (percent homology) with the referenced protein.
  • the functional equivalence of a variant nucleic acid or protein may be evaluated using any method known in the art.
  • variant nucleic acids or proteins may also have a reduced level of activity compared to a reference nucleic acid or protein.
  • a variant nucleic acid may have a reduced level of expression or a variant enzyme may have a reduced ability to catalyze a particular reaction compared to a reference nucleic acid or enzyme, respectively.
  • Enzyme assays and kits for assessing the activity of enzymes in the lactate biosynthesis pathway are known in the art (Wang, J Bacteriol, 195: 4373-4386, 2013; Sigma-Aldrich (MAK066), Thermo (88953); Worthington Biochemical Corporation (LS002755)).
  • Nucleic acids may be delivered to a bacterium of the invention using any method known in the art.
  • nucleic acids may be delivered as naked nucleic acids or may be formulated with one or more agents (e.g., liposomes).
  • Restriction inhibitors may be used in certain embodiments (Murray, Microbiol Molec Biol Rev, 64: 412-434, 2000).
  • transformation including transduction or transfection
  • transformation may be achieved by electroporation, ultrasonication, polyethylene glycol-mediated transformation, chemical or natural competence, protoplast transformation, prophage induction, or conjugation (see, e.g., Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
  • Clostridia including Clostridium acetobutylicum (Mermelstein, Biotechnol, 10: 190-195, 1992), and Clostridium cellulolyticum (Jennert, Microbiol, 146: 3071-3080, 2000).
  • Clostridium scatologenes Parthasarathy, Development of a Genetic Modification System in Clostridium scatologenes ATCC 25775 for Generation of Mutants, Masters Project, Western Kentucky University, 2010
  • conjugation been described for many Clostridia , including Clostridium difficile (Herbert, FEMS Microbiol Lett, 229: 103-110, 2003) and Clostridium acetobuylicum (Williams, J Gen Microbiol, 136: 819-826, 1990).
  • it may be necessary to methylate a nucleic acid before introduction of the nucleic acid into the bacterium of the invention WO 2012/105853).
  • nucleic acid, protein, or microorganism indicates that a nucleic acid, protein, or microorganism is the product of genetic modification, mutation, or recombination.
  • the term “recombinant” refers to a nucleic acid, protein, or microorganism that contains or is encoded by genetic material derived from multiple sources, such as two or more different strains or species of microorganisms.
  • the term “recombinant” may also be used to describe a microorganism that comprises a mutated nucleic acid or protein, including a mutated form of an endogenous nucleic acid or protein.
  • a “parental bacterium” is a bacterium used to generate a bacterium of the invention.
  • the parental bacterium may be a naturally-occurring bacterium (i.e., a wild-type bacterium) or a bacterium that has been previously modified (i.e., a mutant or recombinant bacterium).
  • the bacterium of the invention may be modified to express a lower amount of an enzyme compared to the parental bacterium, or the bacterium of the invention may be modified to not express an enzyme that is expressed by the parental bacterium.
  • the parental bacterium is Clostridium autoethanogenum, Clostridium ljungdahlii , or Clostridium ragsdalei .
  • the parental bacterium is Clostridium autoethanogenum deposited under DSMZ accession DSM23693 (i.e., Clostridium autoethanogenum LZ1561).
  • the term “derived from” indicates that a nucleic acid, protein, or microorganism is modified or adapted from a different (e.g., a parental or wild-type) nucleic acid, protein, or microorganism, so as to produce a new nucleic acid, protein, or microorganism. Such modifications or adaptations typically include insertion, deletion, mutation, or substitution of nucleic acids or genes.
  • the bacterium of the invention is derived from a parental bacterium.
  • the bacterium of the invention is derived from Clostridium autoethanogenum, Clostridium ljungdahlii , or Clostridium ragsdalei .
  • the bacterium of the invention is derived from Clostridium autoethanogenum LZ1561, which is deposited under DSMZ accession DSM23693.
  • the parental bacterium is selected from the group of carboxydotrophic acetogenic bacteria comprising the species Clostridium autoethanogenum, Clostridium ljungdahlii, Clostridium ragsdalei, Clostridium coskatii, Clostridium carboxidivorans, Clostridium drakei, Clostridium scatologenes, Clostridium aceticum, Clostridium formicoaceticum, Clostridium magnum, Acetobacterium woodii, Alkalibaculum bacchii, Moorella thermoacetica, Sporomusa ovate, Butyribacterium methylotrophicum, Blautia producta, Eubacterium limosum , and Thermoanaerobacter kiuvi .
  • carboxydotrophic acetogenic bacteria comprising the species Clostridium autoethanogenum, Clostridium ljungdahlii, Clostridium rags
  • carboxydotrophic acetogenic bacteria are defined by their ability to grow chemoautotrophically on gaseous one-carbon sources such as carbon monoxide (CO) and carbon dioxide (CO 2 ), use carbon monoxide (CO) and/or hydrogen (H 2 ) as energy sources under anaerobic conditions, and produce acetyl-CoA, acetate, and other products.
  • gaseous one-carbon sources such as carbon monoxide (CO) and carbon dioxide (CO 2 )
  • CO carbon monoxide
  • H 2 hydrogen
  • CODH carbon monoxide dehydrogenase
  • hydrogenase formate dehydrogenase
  • formyl-tetrahydrofolate synthetase methylene-tetrahydrofolate dehydrogenase
  • formyl-tetrahydrofolate cyclohydrolase methylene-tetrahydrofolate reductase
  • CODH/ACS carbon monoxide dehydrogenase/acetyl-CoA synthase
  • acetogens channel a substrate directly into acetyl-CoA, from which products, biomass, and secondary metabolites are formed.
  • the bacterium of the invention is derived from a parental microorganism comprising a lactate dehydrogenase, wherein the bacterium of the invention comprises a disrupting mutation in the lactate dehydrogenase.
  • the parental microorganism may be C. autoethanogenum comprising a nucleic acid sequence comprising GenBank AEI90736.1 or an amino acid sequence comprising GenBank CP006763.1, KEGG CAETHG — 1147, or GenBank HQ876025.1.
  • the parental microorganism may be C.
  • the parental microorganism may be C. ragsdalei comprising a nucleic acid sequence comprising GenBank AEI90737.1 or an amino acid sequence comprising GenBank HQ876026.1.
  • Other parental bacteria may have other nucleic acid and amino acid sequences.
  • a “carboxydotroph” is a microorganism capable of tolerating a high concentration of carbon monoxide (CO).
  • CO carbon monoxide
  • the bacterium of the invention is a carboxydotroph.
  • Clostridium ljungdahlii C-01 ATCC 55988
  • Clostridium ljungdahlii O-52 ATCC 55989
  • Clostridium ragsdalei P11T ATCC BAA-622
  • related isolates such as “ Clostridium coskatii ” (U.S.
  • Clostridium ljungdahlii OTA-1 (Tirado-Acevedo, Production of Bioethanol from Synthesis Gas Using Clostridium ljungdahlii , PhD thesis, North Carolina State University, 2010).
  • strains form a subcluster within the Clostridial rRNA cluster I and their 16S rRNA gene is more than 99% identical with a similar low GC content of around 30%.
  • DNA-DNA reassociation and DNA fingerprinting experiments showed that these strains belong to distinct species (WO 2008/028055).
  • the strains of this cluster are defined by common characteristics, having both a similar genotype and phenotype, and they all share the same mode of energy conservation and fermentative metabolism. Furthermore, the strains of this cluster lack cytochromes and conserve energy via an Rnf complex.
  • the species differentiate in substrate utilization of various sugars (e.g., rhamnose, arabinose), acids (e.g., gluconate, citrate), amino acids (e.g., arginine, histidine), or other substrates (e.g., betaine, butanol).
  • sugars e.g., rhamnose, arabinose
  • acids e.g., gluconate, citrate
  • amino acids e.g., arginine, histidine
  • other substrates e.g., betaine, butanol
  • some of the species were found to be auxotrophic to certain vitamins (e.g., thiamine, biotin) while others were not.
  • the organization and number of Wood-Ljungdahl pathway genes, responsible for gas uptake, has been found to be the same in all species, despite differences in nucleic and amino acid sequences (Köpke, Curr Opin Biotechnol , 22: 320-325, 2011).
  • acetogen is a microorganism that generates or is capable of generating acetate as a product of anaerobic respiration.
  • acetogens are obligately anaerobic bacteria that use the Wood-Ljungdahl pathway as their main mechanism for energy conservation and for synthesis of acetyl-CoA and acetyl-CoA-derived products, such as acetate (Ragsdale, Biochim Biophys Acta, 1784: 1873-1898, 2008).
  • the bacterium of the invention is an acetogen.
  • the invention further provides a method of producing a product comprising culturing the bacterium of the invention in the presence of a substrate comprising CO whereby the bacterium of the invention produces a product.
  • the term “substrate” refers to a carbon and/or energy source for the bacterium of the invention.
  • the substrate is a gaseous substrate that comprises carbon monoxide (CO).
  • the substrate may comprise a major proportion of CO, such as about 20% to 100%, 20% to 70%, 30% to 60%, or 40% to 55% CO by volume.
  • the substrate comprises about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% CO by volume.
  • the bacterium of the invention generally converts at least a portion of the CO in the substrate to a product.
  • the substrate may comprise an approximate ratio of H 2 :CO of 2:1, 1:1, or 1:2.
  • the substrate comprises less than about 30%, 20%, 15%, or 10% H 2 by volume.
  • the substrate comprises low concentrations of H 2 , for example, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% H 2 .
  • the substrate contains substantially no H 2 .
  • the substrate may also contain carbon dioxide (CO 2 ), for example, about 1% to 80% or 1% to 30% CO 2 by volume. In one embodiment, the substrate comprises less than about 20% CO 2 by volume. In further embodiments, the substrate comprises less than about 15%, 10%, or 5% CO 2 by volume. In another embodiment, the substrate contains substantially no CO 2 .
  • CO 2 carbon dioxide
  • the substrate is typically gaseous
  • the substrate may also be provided in alternative forms.
  • the substrate may be dissolved in a liquid saturated with a CO-containing gas using a microbubble dispersion generator (Hensirisak, Appl Biochem Biotechnol, 101: 211-227, 2002).
  • the substrate may be adsorbed onto a solid support.
  • the substrate may be a waste gas obtained as a by-product of an industrial process or from some other source, such as from automobile exhaust fumes or biomass gasification.
  • the industrial process is selected from the group consisting of ferrous metal products manufacturing, such as a steel mill manufacturing, non-ferrous products manufacturing, petroleum refining processes, coal gasification, electric power production, carbon black production, ammonia production, methanol production, and coke manufacturing.
  • the CO-containing gas may be captured from the industrial process before it is emitted into the atmosphere, using any convenient method.
  • the CO may be a component of syngas, i.e., a gas comprising carbon monoxide and hydrogen.
  • the CO produced from industrial processes is normally flared off to produce CO 2 and therefore the invention has particular utility in reducing CO 2 greenhouse gas emissions.
  • the composition of the substrate may have a significant impact on the efficiency and/or cost of the reaction. For example, the presence of oxygen (O 2 ) may reduce the efficiency of an anaerobic fermentation process.
  • oxygen O 2
  • the bacterium of the invention may be cultured to produce one or more products.
  • the bacterium of the invention produces one or more products selected from the group consisting of ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate.
  • the bacterium of the invention may also produce other products, such as acetolactate or acetoin malate.
  • the bacterium of the invention produces an increased amount of one or more of ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate compared to a parental bacterium.
  • the bacterium of the invention may produce about 1%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, or 500% more of one or more products compared to the parental bacterium from which the bacterium of the invention is derived.
  • This increase in product production may be due, at least in part, to the disrupting mutation in the lactate biosynthesis pathway enzyme, which diverts carbon and energy away from the production of lactate and towards the production of other products.
  • main product refers to the single product produced in the highest concentration and/or yield.
  • the main product is ethanol or 2,3-butanediol.
  • disrupting the conversion of pyruvate to lactate may favor the production of 2,3-butanediol, formate, malate, fumarate, citrate, succinate and 2-oxogluterate over the production of valine, leucine and isoleucine.
  • a product e.g., citrate
  • salt e.g., citrate
  • acid e.g., citric acid
  • a mixture of the salt and acid forms of the product will be present in a fermentation broth, in a ratio that varies depending on the pH of the broth.
  • acetate encompasses acetate and acetic acid
  • formate encompasses formate and formic acid
  • malate encompasses malate and malic acid
  • lactate encompasses lactate and lactic acid.
  • any compound herein which may exist in one or more isomeric forms should be taken generally to encompass any one or more such isomers of the compound.
  • reference to “lactate” generally encompasses both the D and L isomers of lactate.
  • the culture is performed in a bioreactor.
  • the term “bioreactor” includes a culture/fermentation device consisting of one or more vessels, towers, or piping arrangements, such as a continuous stirred tank reactor (CSTR), immobilized cell reactor (ICR), trickle bed reactor (TBR), bubble column, gas lift fermenter, static mixer, or other vessel or other device suitable for gas-liquid contact.
  • the bioreactor may comprise a first growth reactor and a second culture/fermentation reactor.
  • the substrate may be provided to one or both of these reactors.
  • the terms “culture” and “fermentation” are used interchangeably. These terms encompass both the growth phase and product biosynthesis phase of the culture/fermentation process.
  • the culture is generally maintained in an aqueous culture medium that contains nutrients, vitamins, and/or minerals sufficient to permit growth of the bacterium.
  • the aqueous culture medium is a minimal anaerobic microbial growth medium. Suitable media are known in the art and described, for example, in U.S. Pat. No. 5,173,429, U.S. Pat. No. 5,593,886, and WO 2002/008438.
  • the culture/fermentation should desirably be carried out under appropriate conditions for production of the target product.
  • Reaction conditions to consider include pressure (or partial pressure of CO), temperature, gas flow rate, liquid flow rate, media pH, media redox potential, agitation rate (if using a continuous stirred tank reactor), inoculum level, maximum gas substrate concentrations to ensure that CO in the liquid phase does not become limiting, and maximum product concentrations to avoid product inhibition.
  • the rate of introduction of the CO-containing substrate may be controlled to ensure that the concentration of CO in the liquid phase does not become limiting, since products may be consumed by the culture under CO-limited conditions.
  • increasing the efficiency when used in relation to a fermentation process, include, but are not limited to, increasing one or more of the rate of growth of microorganisms catalyzing the fermentation, the growth and/or product production rate, the volume of desired product (such as alcohols) produced per volume of substrate consumed, the rate of production or level of production of the desired product, and the relative proportion of the desired product produced compared with other by-products of the fermentation.
  • a bioreactor operated at 10 atmospheres of pressure need only be one tenth the volume of a bioreactor operated at 1 atmosphere of pressure.
  • WO 2002/008438 describes gas-to-ethanol fermentations performed under pressures of 30 psig and 75 psig, giving ethanol productivities of 150 g/L/day and 369 g/L/day, respectively. In contrast, fermentations performed using similar media and input gas compositions at atmospheric pressure were found to produce between 10 and 20 times less ethanol per litre per day.
  • the method of the invention may further comprise recovering or purifying one or more products.
  • ethanol or a mixed alcohol stream containing ethanol and/or other products may be recovered from a fermentation broth by any method known in the art, including fractional distillation, evaporation, pervaporation, or extractive fermentation (e.g., liquid-liquid extraction).
  • Byproducts such as acetate or acids, may also be recovered from a fermentation broth using any method known in the art, including activated charcoal adsorption systems, electrodialysis, or continuous gas stripping.
  • a product may be recovered from a fermentation broth by continuously removing a portion of the broth from the bioreactor, separating microbial cells from the broth (conveniently by filtration), and recovering the product from the broth. The separated microbial cells may be returned to the bioreactor. Additionally, cell-free permeate may also be returned to the bioreactor after the product has been removed, optionally with supplementation of nutrients, such as B vitamins.
  • Succinate can be recovered from a fermentation broth using, for example, acidification, electrodialysis coupled with ion-exchange chromatography (Song, Enzyme Microb Technol, 39: 352-361, 2006), precipitation with Ca(OH) coupled with filtration and addition of sulfuric acid (Lee, Appl Microbiol Biotechnol , 79: 11-22, 2008), or reactive extraction with amine-based extractants such as tri-n-octylamine (Huhet, Proc Biochem 41: 1461-1465, 2006).
  • succinic acid it is crucial to have the free acid form, not the salt.
  • Most biotechnological production processes for succinic acid operate at a neutral or slightly acidic pH of 6-7.
  • Branched-chain amino acids such as valine, leucine, and isoleucine, may be recovered from a fermentation broth using concentration (e.g., via reverse osmosis), crystallization or removal of the biomass (e.g., via ultrafiltration or centrifugation), or ion exchange chromatography (Ikeda, Microbial Production of L-Amino Acids, 1-35, 2003).
  • 2,3-butanediol, formate, 2-oxogluterate, and other products may be recovered from a fermentation broth using any method known in the art.
  • low concentrations of 2,3-butanediol may be recovered using membrane techniques, such as electrodialysis, involving the application of a suitable potential across a selective ion permeable membrane.
  • membrane techniques such as electrodialysis, involving the application of a suitable potential across a selective ion permeable membrane.
  • suitable techniques include nanofiltration, wherein monovalent ions selectively pass through a membrane under pressure.
  • This example describes general materials and methods.
  • C. autoethanogenum DSM10061 and DSM23693 (a derivate of DSM10061) and C. ljungdahlii DSM13528 were sourced from DSMZ (The German Collection of Microorganisms and Cell Cultures, Inhoffenstra ⁇ e 7 B, 38124 Braunschweig, Germany).
  • C. ragsdalei ATCC BAA-622 was sourced from ATCC (American Type Culture Collection, Manassas, Va. 20108, USA).
  • E. coli DH5 ⁇ was sourced from Invitrogen (Carlsbad, Calif. 92008, USA).
  • E. coli was grown aerobic at 37° C. in LB (Luria-Bertani) medium. Solid media contained 1.5% agar.
  • Clostridium strains were grown at 37° C. in PETC medium at pH 5.6 using standard anaerobic techniques (Hungate, Methods Microbiol , 3B: 117-132, 1969; Wolfe, Adv Microbiol Physiol, 6: 107-146, 1971). Fructose (heterotrophic growth) or 30 psi CO-containing steel mill gas (collected from New Zealand Steel site in Glenbrook, NZ; composition: 44% CO, 32% N 2 , 22% CO 2 , 2% H 2 ) in the headspace (autotrophic growth) was used as substrate. For solid media, 1.2% bacto agar (BD, Franklin Lakes, N.J. 07417, USA) was added.
  • PETC medium component PETC medium NH 4 Cl 1 g KCl 0.1 g MgSO 4 •7H 2 O 0.2 g NaCl 0.8 g KH 2 PO 4 0.1 g CaCl 2 0.02 g
  • Trace metal solution see below
  • 10 ml Wolfe's vitamin solution see below
  • 10 ml Yeast extract optionalal
  • 1 g Resazurin (2 g/L stock) 0.5 ml NaHCO 3 2 g
  • Reducing agent solution see below
  • Fermentations with C. autoethanogenum DSM23693 were carried out in 1.5 L bioreactors at 37° C. using CO-containing steel mill gas as sole energy and carbon source.
  • a defined medium was prepared, containing: MgCl, CaCl 2 (0.5 mM), KCl (2 mM), H 3 PO 4 (5 mM), Fe (100 ⁇ M), Ni, Zn (5 ⁇ M), Mn, B, W, Mo, Se (2 ⁇ M). The medium was transferred into the bioreactor and autoclaved at 121° C. for 45 minutes.
  • the medium was supplemented with thiamine, pantothenate (0.05 mg/l), and biotin (0.02 mg/l) and reduced with 3 mM cysteine-HCl.
  • the reactor vessel was sparged with nitrogen through a 0.2 ⁇ m filter.
  • the gas was switched to CO-containing steel mill gas, feeding continuously to the reactor. The gas flow was initially set at 80 ml/min and increased to 200 ml/min during mid-exponential phase, while the agitation was increased from 200 rpm to 350 rmp. Na 2 S was dosed into the bioreactor at 0.25 ml/hr.
  • the bioreactor was switched to continuous mode at a rate of 1.0 ml/min (dilution rate 0.96 d ⁇ 1 ). Samples were taken to measure the biomass and metabolites. Additionally, headspace analysis of the in- and out-flowing gas was performed on regular basis.
  • Channel 1 was a 10 m Mol-sieve column running at 70° C., 200 kPa argon and a backflush time of 4.2 s
  • channel 2 was a 10 m PPQ column running at 90° C., 150 kPa helium and no backflush.
  • the injector temperature for both channels was 70° C. Runtimes were set to 120 s, but all peaks of interest would usually elute before 100 s.
  • HPLC analysis of metabolic end products was performed using an Agilent 1100 Series HPLC system equipped with a RID (Refractive Index Detector) operated at 35° C. and an Alltech IOA-2000 organic acid column (150 ⁇ 6.5 mm, particle size 5 ⁇ m) kept at 60° C. Slightly acidified water was used (0.005 M H 2 SO 4 ) as mobile phase with a flow rate of 0.7 ml/min.
  • 400 ⁇ l samples were mixed with 100 ⁇ l of a 2% (w/v) 5-sulfosalicylic acid and centrifuged at 14,000 ⁇ g for 3 min to separate precipitated residues. 10 ⁇ l of the supernatant were then injected into the HPLC for analyses.
  • GC analysis of metabolic end products was performed using an Agilent 6890N headspace GC equipped with a Supelco PDMS 100 1 cm fiber, an Alltech EC-1000 (30 m ⁇ 0.25 mm ⁇ 0.25 ⁇ m) column, and a flame ionization detector (FID). 5 ml samples were transferred into a Hungate tube, heated to 40° C. in a water bath and exposed to the fiber for exactly 5 min. The injector was kept at 250° C. and helium with a constant flow of 1 ml/min was used as carrier gas. The oven program was 40° C. for 5 min, followed by an increase of 10° C./min up to 200° C. The temperature was then further increased to 220° C.
  • FID flame ionization detector
  • the FID was kept at 250° C. with 40 ml/min hydrogen, 450 ml/min air and 15 ml/min nitrogen as make up gas.
  • C. autoethanogenum DSM23693 was grown in YTF medium in the presence of reducing agents and with 30 psi steel mill waste gas (collected from New Zealand Steel site in Glenbrook, NZ; composition: 44% CO, 32% N 2 , 22% CO 2 , 2% H 2 ) at 37° C. using standard anaerobic techniques (Hungate, Methods Microbiol, 3B: 117-132, 1969; Wolfe, Adv Microbiol Physiol, 6: 107-146, 1971).
  • a 50 ml culture of C. autoethanogenum DSM23693 was subcultured to fresh YTF media for 5 consecutive days. These cells were used to inoculate 50 ml YTF media containing 40 mM DL-threonine at an OD 600 nm of 0.05. When the culture reached an OD 600 nm of 0.5, the cells were incubated on ice for 30 minutes and then transferred into an anaerobic chamber and harvested at 4,700 ⁇ g and 4° C.
  • the culture was twice washed with ice-cold electroporation buffer (270 mM sucrose, 1 mM MgCl 2 , 7 mM sodium phosphate, pH 7.4) and finally suspended in a volume of 600 ⁇ l fresh electroporation buffer.
  • This mixture was transferred into a pre-cooled electroporation cuvette with a 0.4 cm electrode gap containing 2 ⁇ g of the methylated plasmid mix and 1 ⁇ l type 1 restriction inhibitor (Epicentre Biotechnologies) and immediately pulsed using the Gene pulser Xcell electroporation system (Bio-Rad) with the following settings: 2.5 kV, 600 ⁇ , and 25 ⁇ F. Time constants of 3.7-4.0 ms were achieved.
  • the culture was transferred into 5 ml fresh YTF medium. Regeneration of the cells was monitored at a wavelength of 600 nm using a Spectronic Helios Epsilon Spectrophotometer (Thermo) equipped with a tube holder. After an initial drop in biomass, the cells started growing again. Once the biomass doubled from that point, about 200 ⁇ l of culture was spread on YTF-agar plates and PETC agar plates containing 5 g/ 1 fructose (both containing 1.2% bacto agar and 15 ⁇ g/ml thiamphenicol). After 3-4 days of incubation with 30 psi steel mill gas at 37° C., 500 colonies per plate were clearly visible.
  • C. autoethanogenum To verify the identity of the six clones and the DNA transfer, genomic DNA was isolated from all 6 colonies/clones in PETC liquid media using PURELINKTM Genomic DNA mini kit (Invitrogen) according to manufacturer's instruction. These genomic DNA along with that of wild-type C. autoethanogenum DSM23693 were used as a template in PCR. The PCR was performed with iproof High Fidelity DNA Polymerase (Bio-Rad Labratories), specific primers as described in examples below and the following program: initial denaturation at 98° C. for 2 min, followed by 25 cycles of denaturation (98° C. for 10 s), annealing (61° C. for 15 s) and elongation (72° C. for 90 s), before a final extension step (72° C. for 7 min). The genomic DNA from wild-type C. autoethanogenum DSM23693 was used as template in control PCR.
  • PCR was also performed against the 16s rRNA gene using primers fD1 (SEQ ID NO: 10) and rP2 (SEQ ID NO: 11) and using PCR conditions as described above.
  • the PCR products were purified using Zymo CLEAN AND CONCENTRATORTM kit and sequenced using primer rP2.
  • This example demonstrates the genetic modification of C. autoethanogenum to eliminate lactate dehydrogenase activity.
  • a knock out construct was designed to disrupt ldh by double homologous recombination. Approximately 1 kb homology arms (SEQ ID NOs: 1-2) flanking the ldh gene were cloned into pMTL85151 plasmid ( FIG. 1 ) and the resulting plasmid pMTL85151-ldh-ko (SEQ ID NO: 3). Standard recombinant DNA and molecular cloning techniques are known in the art (Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Ausubel, Current Protocols in Molecular Biology. Wiley, 1987). Genomic DNA from C. autoethanogenum DSM23693 was isolated using Purelink Genomic DNA mini kit from Invitrogen, according to the manufacturer's instruction.
  • Transformation to introduce DNA was carried out as described above or in WO 2012/053905.
  • ClosTron (Heap, J Microbiol Methods, 70: 452-464, 2007), an intron design tool hosted on the ClosTron website, was used to design a 344 bp targeting region 129s (SEQ ID NO: 8) and identify a target site (SEQ ID NO: 9).
  • the targeting region was chemically synthesized in the vector pMTL007C-E2 containing a retro-transposition activated ermB marker (RAM) by DNA2.0 (Menlo Park) (SEQ ID NO: 12).
  • the vectors were introduced into C. autoethanogenum as described in WO 2012/053905.
  • Single colonies grown on PETC MES with 15 ⁇ g/ml thiamphenicol were streaked on PETC MES with 5 ⁇ g/ml clarothromycin. Colonies from each target were randomly picked and screened for the insertion using flanking primers 155F (SEQ ID NO: 4), and 939R (SEQ ID NO: 5).
  • Amplification was performed using the iNtron Maxime PCR premix.
  • a PCR product of 100 bp indicated a wild-type genotype, while a product size of approximately 1.9 kb suggests the insertion of the group II intron in the target site ( FIG. 3 ).
  • the loss of the plasmid was checked by amplification of the resistance marker (catP) and the gram positive origin of replication (pCB102) ( FIG. 4 ).
  • This example describes growth experiments comparing the product profile of C. autoethanogenum strains with inactivated lactate dehydrogenase to unmodified C. autoethanogenum.
  • Cultures of C. autoethanogenum and a C. autoethanogenum strain with an inactivated lactate dehydrogenase were grown in PETC media with 10 g/L MES buffer in serum bottles.
  • the inoculum was 10% of the media volume and the volume of the media was 10 ml.
  • the cultures were gassed with steel mill off-gas (44% CO, 22% CO 2 , 2% H 2 , 32% N 2 ) 30 psi and incubated at 37° C.
  • the pH of the media was 5.7.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
US14/609,420 2014-01-30 2015-01-29 Recombinant microorganisms and methods of use thereof Abandoned US20150210987A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/609,420 US20150210987A1 (en) 2014-01-30 2015-01-29 Recombinant microorganisms and methods of use thereof
US16/856,841 US11549103B2 (en) 2014-01-30 2020-04-23 Recombinant microorganisms and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933815P 2014-01-30 2014-01-30
US201461944541P 2014-02-25 2014-02-25
US14/609,420 US20150210987A1 (en) 2014-01-30 2015-01-29 Recombinant microorganisms and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/856,841 Division US11549103B2 (en) 2014-01-30 2020-04-23 Recombinant microorganisms and methods of use thereof

Publications (1)

Publication Number Publication Date
US20150210987A1 true US20150210987A1 (en) 2015-07-30

Family

ID=53678453

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/609,420 Abandoned US20150210987A1 (en) 2014-01-30 2015-01-29 Recombinant microorganisms and methods of use thereof
US16/856,841 Active US11549103B2 (en) 2014-01-30 2020-04-23 Recombinant microorganisms and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/856,841 Active US11549103B2 (en) 2014-01-30 2020-04-23 Recombinant microorganisms and methods of use thereof

Country Status (12)

Country Link
US (2) US20150210987A1 (fr)
EP (1) EP3099783A4 (fr)
JP (1) JP6783658B2 (fr)
KR (2) KR20220056885A (fr)
CN (1) CN106133132A (fr)
AU (1) AU2015210892B2 (fr)
BR (1) BR112016017092B1 (fr)
CA (1) CA2936252C (fr)
EA (1) EA036071B1 (fr)
MY (1) MY178451A (fr)
WO (1) WO2015116874A1 (fr)
ZA (1) ZA201604870B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162115B2 (en) 2017-06-30 2021-11-02 Inv Nylon Chemicals Americas, Llc Methods, synthetic hosts and reagents for the biosynthesis of hydrocarbons
US11505809B2 (en) 2017-09-28 2022-11-22 Inv Nylon Chemicals Americas Llc Organisms and biosynthetic processes for hydrocarbon synthesis
US11634733B2 (en) 2017-06-30 2023-04-25 Inv Nylon Chemicals Americas, Llc Methods, materials, synthetic hosts and reagents for the biosynthesis of hydrocarbons and derivatives thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210134988A (ko) * 2019-07-11 2021-11-11 란자테크, 인크. 가스 이용률을 최적화하는 방법
CN111089914A (zh) * 2019-11-07 2020-05-01 河北首朗新能源科技有限公司 微生物发酵生产乙醇中代谢物的高效液相检测方法
CN111154683B (zh) * 2020-01-19 2022-05-13 南京工业大学 一种食甲基丁酸杆菌的优化培养方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042265A1 (en) * 2005-05-04 2009-02-12 Anthony Atkinson Thermophilic Microorganisms with Inactivated Lactate Dehydrogenase Gene (LDH) for Ethanol Production
WO2012109578A2 (fr) * 2011-02-11 2012-08-16 The Trustees Of Dartmouth College Souches de clostridium thermocellum pour production améliorée d'éthanol et leur procédé d'utilisation
US20130157322A1 (en) * 2010-08-26 2013-06-20 Lanzatech New Zealand Limited Process for producing ethanol and ethylene via fermentation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173429A (en) 1990-11-09 1992-12-22 The Board Of Trustees Of The University Of Arkansas Clostridiumm ljungdahlii, an anaerobic ethanol and acetate producing microorganism
US5593886A (en) 1992-10-30 1997-01-14 Gaddy; James L. Clostridium stain which produces acetic acid from waste gases
UA72220C2 (uk) 1998-09-08 2005-02-15 Байоенджініерінг Рісорсиз, Інк. Незмішувана з водою суміш розчинник/співрозчинник для екстрагування оцтової кислоти, спосіб одержання оцтової кислоти (варіанти), спосіб анаеробного мікробного бродіння для одержання оцтової кислоти (варіанти), модифікований розчинник та спосіб його одержання
DE60121335T2 (de) 2000-07-25 2007-08-02 Emmaus Foundation, Inc., Fayetteville Verfahren zur steigerung der ethanolproduktion bei der mikrobiellen fermentation
US7704723B2 (en) 2006-08-31 2010-04-27 The Board Of Regents For Oklahoma State University Isolation and characterization of novel clostridial species
KR101375029B1 (ko) 2007-11-13 2014-03-14 란자테크 뉴질랜드 리미티드 신규 세균 및 이의 이용 방법
GB2478791A (en) * 2010-03-19 2011-09-21 Qteros Inc Ethanol production by genetically-modified bacteria
US8143037B2 (en) 2010-03-19 2012-03-27 Coskata, Inc. Ethanologenic Clostridium species, Clostridium coskatii
WO2012015317A1 (fr) 2010-07-28 2012-02-02 Lanzatech New Zealand Limited Nouvelles bactéries et procédés pour les utiliser
US20110236941A1 (en) 2010-10-22 2011-09-29 Lanzatech New Zealand Limited Recombinant microorganism and methods of production thereof
US20110256600A1 (en) 2011-02-02 2011-10-20 Lanzatech New Zealand Limited Recombinant Microorganisms and Methods of Use Thereof
US8692024B2 (en) * 2011-02-14 2014-04-08 Eastman Renewable Materials, Llc Method of producing n-butyraldehyde
EP2710117B1 (fr) * 2012-01-31 2016-04-27 Lanzatech New Zealand Limited Micro-organismes recombinés et leurs procédés d'utilisation
US20130323820A1 (en) * 2012-06-01 2013-12-05 Lanzatech New Zealand Limited Recombinant microorganisms and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042265A1 (en) * 2005-05-04 2009-02-12 Anthony Atkinson Thermophilic Microorganisms with Inactivated Lactate Dehydrogenase Gene (LDH) for Ethanol Production
US20130157322A1 (en) * 2010-08-26 2013-06-20 Lanzatech New Zealand Limited Process for producing ethanol and ethylene via fermentation
WO2012109578A2 (fr) * 2011-02-11 2012-08-16 The Trustees Of Dartmouth College Souches de clostridium thermocellum pour production améliorée d'éthanol et leur procédé d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diekert et al. J. Bacerol 1978, pp 597-606. *
Jung et al. APPLD Micriobiol and Biotech 2012, 95, pp 461-469. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162115B2 (en) 2017-06-30 2021-11-02 Inv Nylon Chemicals Americas, Llc Methods, synthetic hosts and reagents for the biosynthesis of hydrocarbons
US11634733B2 (en) 2017-06-30 2023-04-25 Inv Nylon Chemicals Americas, Llc Methods, materials, synthetic hosts and reagents for the biosynthesis of hydrocarbons and derivatives thereof
US11505809B2 (en) 2017-09-28 2022-11-22 Inv Nylon Chemicals Americas Llc Organisms and biosynthetic processes for hydrocarbon synthesis

Also Published As

Publication number Publication date
US11549103B2 (en) 2023-01-10
MY178451A (en) 2020-10-13
CN106133132A (zh) 2016-11-16
EP3099783A4 (fr) 2017-09-20
EA201691383A1 (ru) 2017-01-30
KR20220056885A (ko) 2022-05-06
KR20160113129A (ko) 2016-09-28
AU2015210892A1 (en) 2016-08-11
CA2936252A1 (fr) 2015-08-06
WO2015116874A1 (fr) 2015-08-06
US20200248152A1 (en) 2020-08-06
KR102533454B1 (ko) 2023-05-17
BR112016017092A2 (pt) 2017-10-03
ZA201604870B (en) 2020-05-27
EA036071B1 (ru) 2020-09-22
EP3099783A1 (fr) 2016-12-07
AU2015210892B2 (en) 2019-01-17
CA2936252C (fr) 2019-08-20
JP2017504342A (ja) 2017-02-09
BR112016017092B1 (pt) 2023-11-21
JP6783658B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
US9297026B2 (en) Recombinant microorganisms and methods of use thereof
US11549103B2 (en) Recombinant microorganisms and methods of use thereof
CA2995872C (fr) Bacterie clostridium recombinante et utilisations associees dans la production d'acetone
US9365868B2 (en) Fermentation process for producing isopropanol using a recombinant microorganism
US9834795B2 (en) Recombinant microorganisms and uses therefor
EP3180421B1 (fr) Bactérie génétiquement modifiée dotée d'une activité de déshydrogénase du monoxyde de carbone (codh) réduite
EP3397769B1 (fr) Micro-organisme présentant une activité hydrogénase modifiée
NAGARAJU et al. Patent 2936252 Summary
NZ614459B2 (en) Recombinant microorganisms and uses therefor

Legal Events

Date Code Title Description
AS Assignment

Owner name: LANZATECH NEW ZEALAND LIMITED, NEW ZEALAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGARAJU, SHILPA;AL-SINAWI, BAKIR;DE TISSERA, SASHINI;AND OTHERS;SIGNING DATES FROM 20150226 TO 20150313;REEL/FRAME:035168/0151

AS Assignment

Owner name: VENTURE LENDING & LEASING VII, INC., CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNORS:LANZATECH NEW ZEALAND LIMITED;LANZATECH, INC.;LANZATECH FREEDOM PINES BIOREFINERY LLC;AND OTHERS;REEL/FRAME:040731/0573

Effective date: 20161114

Owner name: VENTURE LENDING & LEASING VIII, INC., CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNORS:LANZATECH NEW ZEALAND LIMITED;LANZATECH, INC.;LANZATECH FREEDOM PINES BIOREFINERY LLC;AND OTHERS;REEL/FRAME:040731/0573

Effective date: 20161114

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: LANZATECH UK LIMITED, ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH PRIVATE LIMITED, ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH HONG KONG LIMITED, ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH FREEDOM PINES BIOREFINERY LLC, ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH, INC., ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH NEW ZEALAND LIMITED, ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VENTURE LENDING & LEASING VII, INC.;VENTURE LENDING & LEASING VIII, INC.;REEL/FRAME:059910/0789

Effective date: 20210311

Owner name: LANZATECH NZ, INC., ILLINOIS

Free format text: CHANGE OF NAME;ASSIGNOR:LANZATECH NEW ZEALAND LIMITED;REEL/FRAME:059911/0400

Effective date: 20211028

AS Assignment

Owner name: LANZATECH NZ, INC., ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE U.S. PATENT NUMBER 8,979,228 PREVIOUSLY RECORDED AT REEL: 059911 FRAME: 0400. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LANZATECH NEW ZEALAND LIMITED;REEL/FRAME:061058/0076

Effective date: 20211028

AS Assignment

Owner name: LANZATECH NZ INC., ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE PATENT NUMBE 9,5348,20 PREVIOUSLY RECORDED AT REEL: 059911 FRAME: 0400. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LANZATECH NEW ZEALAND LIMITED;REEL/FRAME:061084/0646

Effective date: 20211028

Owner name: INC., LANZATECH N, ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE PATENT NUMBE 9,5348,20 PREVIOUSLY RECORDED AT REEL: 059911 FRAME: 0400. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LANZATECH NEW ZEALAND LIMITED;REEL/FRAME:061084/0646

Effective date: 20211028

AS Assignment

Owner name: LANZATECH NZ, INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGARAJU, SHILPA;AL-SINAWI, BAKIR;DE TISSERA, SASHINI;AND OTHERS;SIGNING DATES FROM 20221221 TO 20230102;REEL/FRAME:062467/0588